THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Raid Aljumaily to Programmed Cell Death 1 Receptor

Back to Details
This is a "connection" page, showing publications Raid Aljumaily has written about Programmed Cell Death 1 Receptor.
Raid Aljumaily
Connection Strength
0.473
Programmed Cell Death 1 Receptor
  1. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555.
    View in: PubMed
    Score: 0.164
  2. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019 01; 25(1):141-151.
    View in: PubMed
    Score: 0.154
  3. Harnessing the PD-1 Pathway in Myelodysplastic Syndrome. Am J Ther. 2018 Nov/Dec; 25(6):e711-e712.
    View in: PubMed
    Score: 0.154
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES